Physician profile
Karen L Gregory
NPI 1033218896
$68,103.62
in general payments reported to CMS, 2019-2025
28 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Acute Care (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,944 · 2022: $1,712 · 2023: $17K · 2024: $22K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $9,329 · Food and Beverage: $7,433 · Consulting Fee: $3,875 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,665.84 |
| Travel and Lodging | $9,328.84 |
| Food and Beverage | $7,433.18 |
| Consulting Fee | $3,875.00 |
| Education | $144.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $34,293.09 | 2021-2025 | Dupixent |
| Genentech USA, INC. | $23,354.11 | 2021-2025 | Xolair |
| Astrazeneca Pharmaceuticals Lp | $2,564.58 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Novartis Pharmaceuticals Corporation | $2,220.69 | 2024-2025 | |
| Pfizer INC. | $1,357.66 | 2021-2025 | |
| Glaxosmithkline, LLC. | $929.44 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genentech, INC. | $740.85 | 2023-2025 | Xolair |
| Genzyme Corporation | $507.52 | 2022-2025 | |
| Pharming Healthcare, INC. | $361.64 | 2023-2025 | Ruconest |
| Csl Behring | $309.91 | 2021-2025 | Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $222.52 | 2021-2025 | Hyqvia, Takhzyro |
| Ars Pharmaceuticals Operations, INC. | $179.26 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $155.71 | 2021-2022 | |
| Abbvie INC. | $152.19 | 2022 | |
| Sanofi-Aventis U.S. LLC | $141.49 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $123.72 | 2022-2024 | Tezspire |
| Lilly USA, LLC | $107.64 | 2025 | |
| Alk-Abello, INC | $100.58 | 2021-2023 | Ragwitek, Odactra, Grastek |
| Grifols USA, LLC | $56.39 | 2023-2024 | Xembify |
| Optinose US, INC. | $41.64 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $40.38 | 2022 | |
| Kaleo, INC. | $29.50 | 2021 | |
| Dermavant Sciences, INC. | $25.39 | 2024 | Vtama |
| Covis Pharma Gmbh | $22.80 | 2021 | |
| Hologic Sales and Service, LLC | $22.14 | 2024 | Aptima, Thinprep 2000 Processor |
| Nestle Healthcare Nutrition INC. | $16.06 | 2023 | |
| Alcon Vision LLC | $14.88 | 2021 | |
| Organon LLC | $11.84 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.